Triptolide ameliorates osteoarthritis by regulating nuclear factor kappa B-mediated inflammatory response

Area of Science:

• Rheumatology
• Pharmacology
• Molecular Biology

Background:

• Osteoarthritis (OA) is a prevalent degenerative joint disease impacting quality of life, particularly in older adults.
• Triptolide (TPL), a natural compound from Tripterygium wilfordii, possesses known anti-inflammatory properties.

Purpose of the Study:

• To investigate the therapeutic potential of TPL in experimental OA models.
• To elucidate the underlying molecular mechanisms of TPL's action in OA.

Main Methods:

• Osteoarthritis was induced using monosodium iodoacetate (MIA) or surgical methods in rat models.
• Arthritis severity was assessed via arthritis scores and paw withdrawal thresholds.
• Proinflammatory cytokine levels and gene expression were quantified using ELISA and quantitative real-time PCR.

Main Results:

• TPL significantly alleviated OA symptoms and reduced serum proinflammatory cytokine levels in both MIA- and surgery-induced OA rats.
• In primary chondrocytes, TPL counteracted lipopolysaccharide (LPS)-induced proliferation and apoptosis.
• TPL attenuated the expression of key proinflammatory cytokines, including IL-6, IL-8, IL-1β, IL-12, TNF-α, and INF-γ.

Conclusions:

• TPL demonstrates therapeutic efficacy in experimental OA by suppressing inflammatory responses.
• The mechanism involves the dampening of nuclear factor kappa B (NF-κB) signaling pathway activity.
• This leads to a reduction in proinflammatory cytokine production, highlighting TPL as a potential OA therapeutic agent.